Industry Roundup: Mannatech, FTC On Lunada, Nutroganics, Vitamin Shoppe
This article was originally published in The Tan Sheet
Executive Summary
Mannatech rides Asia-Pacific growth; FTC disputes Lunada claims; Nutroganics sprouts profit; Vitamin Shoppe calms Oregon, Vermont on BMPEA; and more news in brief.
You may also be interested in...
GNC, Vitamin Shoppe Not On Same Page In Solving Similar Growth Challenges
Common thread between the manufacturers and retail chain operators offering their own and other brands extends to relatively recent executive suite shakeups following extended stretches of declining sales growth. GNC reported nearly $70m net income for 2018 after two years of net losses and Vitamin Shoppe trimmed its loss by more than $200m from 2017 to $12.1m.
In Brief
Appropriations subcommittee largely ignores FDA; analysts predict lower Novartis OTC sales; France tightens advertising rules; NAD weighs in on Lunada claims; Global Biotechnologies supplements seized; Tetley tea faces lawsuit for antioxidant claims; more news In Brief.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.